These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 34289026

  • 1. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
    Jetani H, Navarro-Bailón A, Maucher M, Frenz S, Verbruggen C, Yeguas A, Vidriales MB, González M, Rial Saborido J, Kraus S, Mestermann K, Thomas S, Bonig H, Luu M, Monjezi R, Mougiakakos D, Sauer M, Einsele H, Hudecek M.
    Blood; 2021 Nov 11; 138(19):1830-1842. PubMed ID: 34289026
    [Abstract] [Full Text] [Related]

  • 2. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E, Mazagova M, Shao S, Wang X, Quirino H, Woods AK, Hampton EN, Rodgers DT, Kim CH, Schultz PG, Young TS.
    Int J Mol Sci; 2017 Oct 27; 18(11):. PubMed ID: 29077054
    [Abstract] [Full Text] [Related]

  • 3. Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia.
    Kovalovsky D, Yoon JH, Cyr MG, Simon S, Voynova E, Rader C, Wiestner A, Alejo J, Pittaluga S, Gress RE.
    Leukemia; 2021 Sep 27; 35(9):2581-2591. PubMed ID: 33633313
    [Abstract] [Full Text] [Related]

  • 4. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
    Wang J, Chen S, Xiao W, Li W, Wang L, Yang S, Wang W, Xu L, Liao S, Liu W, Wang Y, Liu N, Zhang J, Xia X, Kang T, Chen G, Cai X, Yang H, Zhang X, Lu Y, Zhou P.
    J Hematol Oncol; 2018 Jan 10; 11(1):7. PubMed ID: 29316944
    [Abstract] [Full Text] [Related]

  • 5. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.
    Tashiro H, Sauer T, Shum T, Parikh K, Mamonkin M, Omer B, Rouce RH, Lulla P, Rooney CM, Gottschalk S, Brenner MK.
    Mol Ther; 2017 Sep 06; 25(9):2202-2213. PubMed ID: 28676343
    [Abstract] [Full Text] [Related]

  • 6. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
    Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.
    Blood; 2017 Apr 27; 129(17):2395-2407. PubMed ID: 28246194
    [Abstract] [Full Text] [Related]

  • 7. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
    Lichtman EI, Du H, Shou P, Song F, Suzuki K, Ahn S, Li G, Ferrone S, Su L, Savoldo B, Dotti G.
    Clin Cancer Res; 2021 Jun 01; 27(11):3141-3153. PubMed ID: 33531429
    [Abstract] [Full Text] [Related]

  • 8. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells.
    Yan Z, Gu R, Ma H, Chen N, Zhang T, Xu Y, Qiu S, Xing H, Tang K, Tian Z, Rao Q, Wang M, Wang J.
    Cell Oncol (Dordr); 2024 Oct 01; 47(5):1879-1895. PubMed ID: 39008193
    [Abstract] [Full Text] [Related]

  • 9. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.
    Caulier B, Joaquina S, Gelebart P, Dowling TH, Kaveh F, Thomas M, Tandaric L, Wernhoff P, Katyayini NU, Wogsland C, Gjerstad ME, Fløisand Y, Kvalheim G, Marr C, Kobold S, Enserink JM, Gjertsen BT, McCormack E, Inderberg EM, Wälchli S.
    Cell Rep Med; 2024 Jun 18; 5(6):101572. PubMed ID: 38754420
    [Abstract] [Full Text] [Related]

  • 10. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
    Liu Y, Wang S, Schubert ML, Lauk A, Yao H, Blank MF, Cui C, Janssen M, Schmidt C, Göllner S, Kleist C, Zhou F, Rahfeld JU, Sauer T, Schmitt M, Müller-Tidow C.
    Int J Cancer; 2022 Apr 01; 150(7):1141-1155. PubMed ID: 34766343
    [Abstract] [Full Text] [Related]

  • 11. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    Qin H, Yang L, Chukinas JA, Shah N, Tarun S, Pouzolles M, Chien CD, Niswander LM, Welch AR, Taylor N, Tasian SK, Fry TJ.
    J Immunother Cancer; 2021 Sep 01; 9(9):. PubMed ID: 34531250
    [Abstract] [Full Text] [Related]

  • 12. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.
    Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S.
    Cell; 2018 May 31; 173(6):1439-1453.e19. PubMed ID: 29856956
    [Abstract] [Full Text] [Related]

  • 13. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
    Minagawa K, Jamil MO, Al-Obaidi M, Pereboeva L, Salzman D, Erba HP, Lamb LS, Bhatia R, Mineishi S, Di Stasi A.
    PLoS One; 2016 May 31; 11(12):e0166891. PubMed ID: 27907031
    [Abstract] [Full Text] [Related]

  • 14. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.
    Virgo P, Denning-Kendall PA, Erickson-Miller CL, Singha S, Evely R, Hows JM, Freeman SD.
    Br J Haematol; 2003 Nov 31; 123(3):420-30. PubMed ID: 14617000
    [Abstract] [Full Text] [Related]

  • 15. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
    Atilla PA, McKenna MK, Watanabe N, Mamonkin M, Brenner MK, Atilla E.
    Cytotherapy; 2022 Mar 31; 24(3):282-290. PubMed ID: 34955406
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
    Sommer C, Cheng HY, Nguyen D, Dettling D, Yeung YA, Sutton J, Hamze M, Valton J, Smith J, Djuretic I, Chaparro-Riggers J, Sasu BJ.
    Mol Ther; 2020 Oct 07; 28(10):2237-2251. PubMed ID: 32592688
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
    Le Q, Castro S, Tang T, Loeb AM, Hylkema T, McKay CN, Perkins L, Srivastava S, Call L, Smith J, Leonti A, Ries R, Pardo L, Loken MR, Correnti C, Fiorenza S, Turtle CJ, Riddell S, Tarlock K, Meshinchi S.
    Clin Cancer Res; 2021 Oct 15; 27(20):5718-5730. PubMed ID: 34380639
    [Abstract] [Full Text] [Related]

  • 18. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
    Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang WC, Bretzlaff W, Chang B, Jonnalagadda M, Starr R, Ostberg JR, Jensen MC, Bhatia R, Forman SJ.
    Blood; 2013 Oct 31; 122(18):3138-48. PubMed ID: 24030378
    [Abstract] [Full Text] [Related]

  • 19. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Driouk L, Gicobi JK, Kamihara Y, Rutherford K, Dranoff G, Ritz J, Baumeister SHC.
    Front Immunol; 2020 Oct 31; 11():580328. PubMed ID: 33384686
    [Abstract] [Full Text] [Related]

  • 20. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
    Ma Q, Garber HR, Lu S, He H, Tallis E, Ding X, Sergeeva A, Wood MS, Dotti G, Salvado B, Ruisaard K, Clise-Dwyer K, John LS, Rezvani K, Alatrash G, Shpall EJ, Molldrem JJ.
    Cytotherapy; 2016 Aug 31; 18(8):985-994. PubMed ID: 27265873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.